Vitralis Biotech
Newsroom
Announcements from Vitralis Biotech.
Media enquiries: press@vitralis.example
Vitralis closes $180M Series C to scale the design loop
Round led by Halcyon Ridge Capital with participation from Northfen Ventures and Lanternway Partners.
CHORUS-9 opens to early-access partners
Twelve partner labs begin running cell-free expression at 9,216 variants per run.
Kestrel Bay pilot plant begins continuous operation
The 20,000 L continuous fermentation line is now producing reagent enzymes for CHORUS-9.